Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Nat Genet ; 54(10): 1534-1543, 2022 Oct.
Article in English | MEDLINE | ID: mdl-36195757

ABSTRACT

Sleep apnea is a common disorder that represents a global public health burden. KCNK3 encodes TASK-1, a K+ channel implicated in the control of breathing, but its link with sleep apnea remains poorly understood. Here we describe a new developmental disorder with associated sleep apnea (developmental delay with sleep apnea, or DDSA) caused by rare de novo gain-of-function mutations in KCNK3. The mutations cluster around the 'X-gate', a gating motif that controls channel opening, and produce overactive channels that no longer respond to inhibition by G-protein-coupled receptor pathways. However, despite their defective X-gating, these mutant channels can still be inhibited by a range of known TASK channel inhibitors. These results not only highlight an important new role for TASK-1 K+ channels and their link with sleep apnea but also identify possible therapeutic strategies.


Subject(s)
Gain of Function Mutation , Sleep Apnea Syndromes , Child , Developmental Disabilities , Humans , Mutation/genetics , Nerve Tissue Proteins , Potassium Channels, Tandem Pore Domain , Sleep Apnea Syndromes/genetics
2.
Biochem Soc Trans ; 49(4): 1855-1865, 2021 08 27.
Article in English | MEDLINE | ID: mdl-34346486

ABSTRACT

Pulmonary arterial hypertension (PAH) is a fatal disease of the cardiopulmonary system that lacks curative treatments. The main pathological event in PAH is elevated vascular resistance in the pulmonary circulation, caused by abnormal vasoconstriction and vascular remodelling. Ion channels are key determinants of vascular smooth muscle tone and homeostasis, and four PAH channelopathies (KCNK3, ABCC8, KCNA5, TRPC6) have been identified so far. However, the contribution of ion channels in other forms of PAH, which account for the majority of PAH patients, has been less well characterised. Here we reason that a variety of triggers of PAH (e.g. BMPR2 mutations, hypoxia, anorectic drugs) that impact channel function may contribute to the onset of the disease. We review the molecular mechanisms by which these 'extrinsic' factors converge on ion channels and provoke their dysregulation to promote the development of PAH. Ion channels of the pulmonary vasculature are therefore promising therapeutic targets because of the modulation they provide to both vasomotor tone and proliferation of arterial smooth muscle cells.


Subject(s)
Ion Channels/metabolism , Pulmonary Arterial Hypertension/metabolism , Animals , Homeostasis , Humans , Muscle Tonus , Muscle, Smooth, Vascular/metabolism , Muscle, Smooth, Vascular/pathology , Pulmonary Arterial Hypertension/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...